Provention Bio invites you to attend a Webcast program titled TZIELD^TM: Potential to Delay Stage 3 T1D. This event will take place on November 16th @ 12:15PM! TZIELD™ (teplizumab-mzwv) is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. This webinar will inform attendees all about it. Learn more below!

Download Flier

Click To RSVP